These patients represent a minority of patients characterized by high fragility and increased cardiovascular risk compared to those with T1D alone, thus benefitting more from switching to degludec insulin, notably in patients who had glycaemic variability and high hypoglycemic episodes. The gene discussed is INS; the disease is type 1 diabetes mellitus.